|
|
|
|
|
|
By Jonathan B. (J.B.) Fitzgerald, Ph.D., Snell & Wilmer L.L.P. | On September 20, 2023, in Baxalta v. Genentech, the Federal Circuit invalidated patent claims directed to functionally claimed antibodies, finding that they failed to satisfy the enablement requirement. The author of this article is a patent attorney, and he shares the key takeaways for biotech/pharma companies going forward. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIFE SCIENCE LEADER MAGAZINE |
|
|
|
Have you heard of Life Science Leader? Check it out today for access to candid interviews with top-tier executives on how they do business. |
|
|